Enliven Therapeutics ELVN Deferred Offering Costs Non Current
Deferred Offering Costs Non Current at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept elvn:DeferredOfferingCostsNonCurrent.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's deferred offering costs non current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's deferred offering costs non current?
- Enliven Therapeutics (ELVN) reported deferred offering costs non current of $217K in Q1 2026.
- What is the long-term trend for Enliven Therapeutics's deferred offering costs non current?
- Over 3 years (2022 to 2025), Enliven Therapeutics's deferred offering costs non current has grown at a -62.1% compound annual growth rate (CAGR), from $3.98M to $217K.
- What does deferred offering costs non current mean?
- This represents capitalized costs directly attributable to a future equity or debt offering that are expected to be realized beyond the next twelve months. These costs are typically deferred until the completion of the financing event, at which point they are reclassified as a reduction of the proceeds or amortized. Monitoring this balance provides insight into the company's planned capital raising activities and the associated transaction-related expenditures.